<DOC>
	<DOC>NCT01251601</DOC>
	<brief_summary>The purpose of this study is to determine whether pregnancy affects the blood concentrations of raltegravir by comparing the second trimester and third trimester drug concentrations with post partum.</brief_summary>
	<brief_title>The Effect of Pregnancy on the PK of IsentressÂ®: A Longitudinal Investigation in the Second and Third Trimesters</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV Infected Pregnant At least 18 years of age Planning to initiate or currently received raltegravir as part of an antiretroviral regimen with plans to continue at least 810 weeks post partum Less than 18 years of age Hemoglobin &lt;9 g/dL or Hematocrit &lt;27.3 at screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>